VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 123-133

  Dagar, Sumeet ^a   Krishnadas, Aparna ^a   Rubinstein, Israel ^a,b   Blend, Michael J ^a   Önyüksel, Hayat ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of Illinois at Chicago   (United States)

Author keywords

Breast cancer imaging; Tc99m HMPAO; Tumor targeting; VIP liposome biodistribution; VIP liposome pharmacokinetics

Indexed keywords

AMINO ACIDS; BIOMARKERS; ENCAPSULATION; PHARMACOKINETICS; RADIOISOTOPES; TISSUE; TUMORS;

STERICALLY STABILIZED LIPOSOMES (SSL); THERAPEUTIC AGENTS;

CONTROLLED DRUG DELIVERY;

AMINO ACID; DIAGNOSTIC AGENT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LIPOSOME; METHYLNITROSOUREA; NEUROPEPTIDE; RADIOPHARMACEUTICAL AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE; CARCINOGEN; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BREAST CANCER; CANCER DIAGNOSIS; CANCER TISSUE; CARCINOMA IN SITU; CONFERENCE PAPER; CONTROLLED STUDY; COVALENT BOND; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG TARGETING; ENCAPSULATION; FEMALE; IN VIVO STUDY; ISOTOPE LABELING; MAMMAL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SURFACE PROPERTY; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG FORMULATION; EXPERIMENTAL NEOPLASM; IMAGE PROCESSING; METABOLISM; NEOPLASM; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; CARCINOGENS; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NEOPLASMS; PARTICLE SIZE; RADIOPHARMACEUTICALS; RATS; TECHNETIUM TC 99M EXAMETAZIME; TISSUE DISTRIBUTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0141886984     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00242-6     Document Type: Conference Paper

References (29)

1. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med. 36:(10):1995;1846-1853.
2. Reubi J.C. In vitro identification of VIP receptors in human tumors: potential clinical implications. Ann. N.Y. Acad. Sci. 805:1996;753-759.
3. Dagar S., Sekosan M., Blend M., Rubinstein I., Onyuksel H. Identification and targeting of VIP receptors in rats with induced breast cancer. Proceedings of an International Symposium on the Controlled Release of Bioactive Materials, Boston, MA :1999;22-23. Vol. 26.
4. Dagar S., Sekosan M., Rubinstein I., Onyuksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res. Treat. 65:(1):2001;49-54.
5. Dagar S., Sekosan M., Lee B.S., Rubinstein I., Onyuksel H. VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J. Controlled Release. 74:(1-3):2001;129-134.
6. Dagar S., Stastny J., Blend M., Rubinstein I., Onyuksel H. Preparation of Tc99m-HMPAO VIP-SSL for breast tumor detection. Pharm. Sci. 1:1998;S294.
7. Patel M., Rubinstein I., Ikezaki H., Alkan-Onyuksel H. Simplified preparation of vasoactive intestinal peptide in sterically stabilized liposomes. Proceedings of an International Symposium on the Controlled Release of Bioactive Materials :1997;913-914. Vol. 24.
8. Phillips W.T., Rudolph A.S., Goins B., Timmons J.H., Klipper R., Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int. J. Radiat. Appl. Instr. B. 19:(5):1992;539-547.
9. Boerman O.C., Oyen W.J., van Bloois L., Koenders E.B., van der Meer J.W., Corstens F.H., Storm G. Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time. J. Nucl. Med. 38:(3):1997;489-493.
10. Kates M. Techniques in Lipidology. 1972;Elsevier, New York.
11. Moon R.C., Kelloff G.J., Detrisac C.J., Steele V.E., Thomas C.F., Sigman C.C. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 12:(4):1992;1147-1153.
12. Udeani G.O., Gerhauser C., Thomas C.F., Moon R.C., Kosmeder J.W., Kinghorn A.D., Moriarty R.M., Pezzuto J.M. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res. 57:(16):1997;3424-3428.
13. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:(12, Pt 1):1986;6387-6392.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:2001;189-207.
15. Ishida O., Maruyama K., Sasaki K., Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm. 190:(1):1999;49-56.
16. Phillips W.T. Delivery of gamma-imaging agents by liposomes. Adv. Drug Deliv. Rev. 37:(1-3):1999;13-32.
17. Phillips W.T. Gregoriadas G., McCormack X. Strategies for Stealth Therapeutic Systems. Targeting of Drugs. Vol. 6:1998;109-129 Plenum Press, New York.
18. Allen T.M., Stuart D.D. Janoff A. Liposomes: Rational Design. 1999;66-71 Marcel Dekker, New York.
19. Zalipsky S., Mullah N., Harding J.A., Gittelman J., Guo L., DeFrees S.A. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug. Chem. 8:(2):1997;111-118.
20. Yang X., Young L.H., Voigt J.M. Expression of a vitamin D-regulated gene (VDUP-1) in untreated- and MNU-treated rat mammary tissue. Breast Cancer Res. Treat. 48:(1):1998;33-44.
21. Oyen W.J., Boerman O.C., Storm G., van Bloois L., Koenders E.B., Claessens R.A., Perenboom R.M., Crommelin D.J., van der Meer J.W., Corstens F.H. Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. J. Nucl. Med. 37:(8):1996;1392-1397.
22. Laverman P., Dams E.T., Oyen W.J., Storm G., Koenders E.B., Prevost R., van der Meer J.W., Corstens F.H., Boerman O.C. A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative. J. Nucl. Med. 40:(1):1999;192-197.
23. Goins B., Klipper R., Rudolph A.S., Phillips W.T. Use of technetium-99m-liposomes in tumor imaging. J. Nucl. Med. 35:(9):1994;1491-1498.
24. Kirpotin D.B., Park J.W., Hong K., Shao Y., Colbern G.T., Zheng W.-w., Meyer O., Benz C.C., Papahadjopoulos D. Lasic D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;Elsevier, Amsterdam.
25. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43:(1):1999;1-7.
26. Harrington K.J., Rowlinson-Busza G., Syrigos K.N., Uster P.S., Abra R.M., Stewart J.S. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br. J. Cancer. 83:(2):2000;232-238.
27. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J Controlled Release. 74:(1-3):2001;95-113.
28. Khleif S.N., Curt G.A. Holland X. Cancer Medicine. 1997;Williams and Wilkins, Baltimore.
29. Kuh H.J., Jang S.H., Wientjes M.G., Weaver J.R., Au J.L. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 290:(2):1999;871-880.